Clinical Trials - Phase I
Filter News
Found 21,051 articles
-
Ionis Revises 2015 Financial Guidance And Provides Pipeline Update In Conjunction With J.P. Morgan Conference
1/12/2016
-
Xcovery Announces Updated Clinical Data On X-396 In Patients With ALK+ Non-Small Cell Lung Cancer At The 4th Xcovery-IASLC International Joint Conference
1/11/2016
-
Immune Design Corporation Receives Orphan Drug Designation From The U.S. FDA For Complementary Components Of CMB305
1/11/2016
-
Cidara Therapeutics Announces Positive Data From Multiple Dose Phase I Clinical Trial Of CD101 IV
1/11/2016
-
DURECT Corporation Announces Initiation Of DUR-928 Dosing In Patients
1/11/2016
-
Bellicum Announces Submission Of BPX-701 And BPX-601 Clinical Trial Protocols For Review By The NIH RAC
1/11/2016
-
Rebiotix And Washington University Treat First Patient With Urinary Tract Infection Utilizing Investigational RBX2660 To Potentially Reverse Multidrug Resistant Organisms
1/11/2016
-
Lycera Announces Celgene Has Exercised Its Option To License Portfolio Of Ex Vivo RORgamma Agonist Compounds Under Global Strategic Collaboration
1/11/2016
-
Eicosis, LLC Receives $4 Million To Develop Novel Treatment For Diabetic Neuropathic Pain
1/11/2016
-
Can-Fite BioPharma Announces 2016 Clinical Milestones For Its Pipeline Of Drugs In Six Indications
1/11/2016
-
OXIS International, Inc. Eliminates Debt In Restructuring Deal, Will Move Forward With Phase 1/Phase 2 Clinical Trial Of Cancer Drug
1/11/2016
-
PTC Therapeutics Outlines Business Priorities For The Development And Commercialization Of Translarna And Progress Of The Company Pipeline
1/11/2016
-
Infinity Pharmaceuticals Inc. Provides Key 2016 Goals And Financial Guidance
1/11/2016
-
aTyr Pharma Provides Corporate Update And Outlook For 2016
1/11/2016
-
Enanta Pharmaceuticals, Inc. Announces New R&D Initiatives In Hepatitis B Virus And Respiratory Syncytial Virus And Plan To Provide Data Updates On Programs In NASH And HCV At The 34th Annual J.P. Morgan Healthcare Conference
1/11/2016
-
Sangamo BioSciences Highlights 2016 Catalysts At The 34th Annual J.P. Morgan Healthcare Conference
1/11/2016
-
ImmunoGen Announces Recent Product Program Advancements And Anticipated 2016 Events In Advance Of J.P. Morgan Healthcare Conference
1/11/2016
-
Protagonist Therapeutics Initiates Phase 1 Study With Oral Peptide PTG-100
1/8/2016
-
Valor Biotherapeutics Announces First Patient Treated In Phase 1 Study Of IGN002
1/8/2016
-
Kolltan Pharmaceuticals Inc. Provides Update On Clinical Pipeline, Corporate Developments And Near-Term Milestones
1/8/2016